Polymyxin B hemoperfusion and mortality in abdominal septic shock

JAMA

Volumn 302, Issue 18, 2009, Pages 1968-

  Vincent, Jean Louis ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

HEMOPERFUSION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RESUSCITATION; SEPSIS; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; NOTE;

ANTI-BACTERIAL AGENTS; HEMOPERFUSION; HUMANS; POLYMYXIN B; SHOCK, SEPTIC;

EID: 70450078425     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1606     Document Type: Letter

References (5)

1. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445-2452.
2. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23(5):400-405. (Pubitemid 40571661)
3. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776-787.
4. Salomão R, Martins PS, Brunialti MK, et al. TLR signaling pathway in patients with sepsis. Shock. 2008;30(suppl 1):73-77.
5. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2):R47. (Pubitemid 46805281)